Skip to main content
Log in

Pharmacokinetics of paroxetine in patients with cirrhosis

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

In a 14-day multiple-dose study the pharmacokinetics of paroxetine was investigated in 12 patients with alcoholic cirrhosis and in 6 subjects without liver disease. The dose of 20–30 mg paroxetine daily was adjusted to the reduction in liver function, as assessed by the galactose elimination capacity. Accordingly, all but two of the cirrhotic patients received 20 mg, while all six control subjects received 30 mg.

Dose-corrected, trough drug concentration at steady state (CSS min) and dose-corrected AUC24h were significantly higher in the patients with liver diseases than in the control subjects [3.4 vs 1.5 ng · ml−1 per mg paroxetine and 89 vs 43 h (ng) · ml−1 per mg paroxetine]. The elimination t1/2 was prolonged [83 vs 36 h], but the difference was not statistically significant, and the cirrhotic patients were still able to clear almost all the paroxetine by metabolism. All but two patients with cirrhosis experienced nausea during the first two or three days after the first dose, while none of the controls had this symptom.

The study showed slower elimination of paroxetine and consequently higher plasma levels in patients with cirrhosis, suggesting that in the latter the dose of paroxetine should be in the lower end of the therapeutic range.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kaye CM, Haddock RE, Langley PF et al. (1989) A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 80 [Suppl 350]: 60–75

    Google Scholar 

  2. Krastev Z, Terziivanov D, Vlahov V et al. (1989) The pharmacokinetics of paroxetine in patients with liver cirrhosis. Acta Psychiatr Scand 80 [Suppl 350]: 91–92

    Google Scholar 

  3. Døssing M, Poulsen HE, Andreasen PB, Tygstrup N (1982) A simple method for determination of antipyrine clearance. Clin Pharmacol Ther 32: 392–397

    Google Scholar 

  4. Tygstrup N (1966) Determination of the hepatic elimination capacity (Lm) of galactose by single dose injection. Scand J Clin Lab Invest 18 [Suppl 92]: 118–125

    Google Scholar 

  5. Tygstrup N (1977) Effect of sites for blood sampling in determination of the galactose elimination capacity. Scand J Clin Lab Invest 37: 333–338

    Google Scholar 

  6. Brett MA, Dierdorf HD, Zussman BD, Coates PE (1987) Determination of paroxetine in human plasma, using high-performance liquid chromatography with fluorescence detection. J Chromatogr 419: 438–444

    Google Scholar 

  7. Lundmark J, Thomsen IS, Fjord-Larsen T et al. (1989) Paroxetine: pharmacokinetic and antidepressant effect in the elderly. Acta Psychiatr Scand 80 [Suppl 350]: 76–80

    Google Scholar 

  8. Døssing M, Pilsgaard H, Rasmussen B, Poulsen HE (1983) Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism. Eur J Clin Pharmacol 25: 215–222

    Google Scholar 

  9. Greb WH, Buscher G, Dierdorf HD, Köster FE, Wolf D, Mellows G (1989) The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine. Acta Psychiatr Scand 80 [Suppl 350]: 95–98

    Google Scholar 

  10. Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JGC (1989) Evaluation of the potential for interactions of paroxetine with cimetidine, warfarin and digoxin. Acta Psychiatr Scand 80 [Suppl 350]: 102–106

    Google Scholar 

  11. Bass L, Keiding S (1988) Physiologically based models and strategic experiments in hepatic pharmacology. Biochem Pharmacol 37: 1425–1431

    Google Scholar 

  12. Sorrentino D, Potter BJ, Berk PD (1990) From albumin to the cytoplasm: the hepatic uptake of organic anions. In: Popper H, Schaffner F (eds) Progress in liver diseases. Saunders, Philadelphia

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dalhoff, K., Almdal, T.P., Bjerrum, K. et al. Pharmacokinetics of paroxetine in patients with cirrhosis. Eur J Clin Pharmacol 41, 351–354 (1991). https://doi.org/10.1007/BF00314966

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00314966

Key words

Navigation